期刊文献+

脂联素基因启动子-11377(C/G)基因多态性与中国2型糖尿病和罗格列酮降糖疗效的相关性研究 被引量:6

Association of adiponectin allele-11377(C/G) polymorphism with type 2 diabetes and rosiglitazone response in Chinese patients
下载PDF
导出
摘要 目的:探讨脂联素基因SNP-11377(C/G)与中国汉族2型糖尿病(T2D)的关系及对罗格列酮降糖疗效的影响。方法:应用PCR-RFLP方法对255名T2D和120名健康对照者进行-11377(C/G)基因分型,选取42个不同基因型的T2D患者每天早饭时口服罗格列酮4mg,连续服药12周。测定用药前后的TG、空腹血糖(FPG)、餐后血糖(PPG)、糖化血红蛋白(HbAlc)、空腹胰岛素(FINS)、餐后胰岛素(PINS)、TC、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、胰岛素抵抗指数(HOMA-IR)和脂联素水平。结果:T2D组SNP-11377等位基因频率与基因型频率明显高于健康对照组(P<0.05),并且随着G等位基因的增加,患者的脂联素水平(P<0.01)明显降低,FINS(P<0.05)和HOMA-IR水平(P<0.05)明显增高。在服用罗格列酮后,CC型FPG、PPG和HOMA-IR的降低幅度明显高于突变型(CG+GG)(P<0.05),而CC型脂联素升高幅度明显高于突变型(P<0.01)。结论:脂联素基因启动子-11377C/G遗传变异与胰岛素抵抗和T2D有关,并且可能影响罗格列酮的降糖疗效。 AIM. To evaluate the impact of adiponectin allele C-11377G genetic polymorphisms on efficacy of rosiglitazone in Chinese patients with type 2 diabetes (T2D). METHODS:Patients with T2D (n = 255) and 120 healthy volunteers were enrolled to identify-11377C/G genotypes by polymerase chain reaction restriction fragment length polymorphism assay. Forty two T2D patients with different-11377C/G genotypes received orally rosiglitazone as a single-dose therapy (4 mg day 1 p. o. ) for 12 weeks. The serum triglyceride, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), giycated hemoglobin(HbAic), fasting serum insulin(FINS), postprandial serum insu lin ( PINS), total cholesterol ( TC), low-density lipoprotein-cholesterol ( LDL-C ), high-density lipoprotein-cholesterol ( HDI. C), homeostasis model assessment for insulin resistance (HOMA-IR), and adiponectin concentration were de termined before and after rosiglitazone treatment. RESULTS:Compared with the health con trol group, the allele frequency of-11377(C/G) and the genotypic frequency were increased in T2D group(P〈0.05), and as the G allele gene increased, the adiponectin level was significantly decreased,and the levels of FINS and HOMA-IR were significantly increased in T2D patients(P〈0.05). After treated with rosiglitazone, the de gree of the decrease of the FPG (P〈0.01), PPG (P〈0.05) and HOMA IR (P〈0.05) levels in the CC genotype was significant higher than that in the other genotypes. However, the degree of the increase of the serum adiponectin concentration(P〈0.01) in the CC genotype was significantly higher than that in the other genotypes. CONCLUSION. These data suggest that the adiponectin allele-11377C/G polymorphisms significantly associated with the pathogenesis of T2D,insulin resistance, and the therapeutic efficacy of rosiglitazone in Chinese patients with T2D.
出处 《中国临床药理学与治疗学》 CAS CSCD 2010年第1期82-88,共7页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金资助项目(30572230)
关键词 脂联素 基因多态性 PCR-RFLP 2型糖尿病 罗格列酮 Adiponectin Genetic polymorphism PCR-RFLP Type 2 diabetes Rosiglitazone
  • 相关文献

参考文献18

  • 1Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes[J]. J Biol Chem, 1995, 270 (45) : 26746--26749.
  • 2Hotta K, Funahashi T, Arita Y. et al. Plasma con centrations of a novel, adipose-specific protein, adi ponectin, in type 2 diabetic patients[J].Arterio scler Thromb Vasc Biol, 2000,20(6): 1595--1599.
  • 3Mori Y, Otabe S, Dina C, et al. Genome-wide search for type 2 diabetes in Japanese affected sibpairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p[J]. Diabetes, 2002,51(4): 1247--1255.
  • 4Maeda N, Takahashi M, Funahashi T, et al. PPAR gamma ligands increase expression and plasma concentrations of adiponectin and adipose derived protein[J]. Diabetes, 2001,50 (9) : 2094-- 2099.
  • 5Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients[J]. Diabetes Care, 2002, 25 (2):376--380.
  • 6Hotta K, Funahashi T, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponec tin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys[J].Diabetes, 2001,50(5) : 1126 --1133.
  • 7Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2005,67(1):43--52.
  • 8Vasseur F, Helbeeque N,Dina C,et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for 2 diabetes in French Caucasians[J]. Hum Mol Genet, 2002, 11 (21) :2607--2614.
  • 9Populaire C, Mori Y, Dina C, et al. Does the - 11377 promoter variant of APM1 gene contribute to the genetic risk for Type 2 diabetes mellitus in Japanese families[J]. Diabetologia, 2003, 46 (3) :443 -- 445.
  • 10Gu HF, Abulaiti A, Ostenson CG,et al. Single nu cleotide polymorphisms in the proximal promoter region of the adiponeetin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians[J]. Diabetes, 2004, 53(Suppl):S31--S35.

二级参考文献11

  • 1宁光,顾卫琼,徐敏,杜鹏飞,洪洁,张翼飞,李小英.脂联素:从胰岛素抵抗到胰岛β细胞功能[J].中华内分泌代谢杂志,2004,20(4). 被引量:12
  • 2Hara K,Boutin P,Mori Y,et al.Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population[J].Diabetes,2002,51:536-540.
  • 3Vasseur F,Helbecque N,Dina C,et al.Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon3 of the APM1 gene modulate adipocyte-secreted adiponectin Hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians[J].Hum Mol Genet,2002,11:2607-2614.
  • 4Gu HF,Abulaiti A,Ostenson C,et al.Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1) gene are associated with type 2 diabetes in Swedish Caucasians[J].Diabetes,2004,53:S31-S35.
  • 5Lindsay R,Funahashi T,Krokoff J,et al.Genome-wide linkage analysis of serum adiponectin in the Pima Indian population[J].Diabetes,2003,52:2419-2425.
  • 6Comuzzie AG,Funahashi T,Sonnenberg G,et al.The genetic basis of plasma variation in adiponectin,a global endophenotype for obesity and the metabolic syndrome[J].J Clin Endocrinol Metab,2001,86:4321-4325.
  • 7Maekawa T,Imamoto F,Merlino GT,et al.Cooperative function of two separate enhancers of the human epidermal growth factor receptor proto-oncogene[J].J Biol Chem,1989,264:5488-5494.
  • 8Weyer C,Funahashi T,Tanaka S,et al.Hypoadiponectinemia in obesity and type 2 diabetes:Close association with insulin resistance and hyperinsulinemia[J].J Clin Endocrinol Metab,2001,86:1930-1935.
  • 9Trujillo ME,Scherer PE.Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome[J].J Intern Med,2005,257(2):167-175.
  • 10Combs TP,Berg AH,Obici S,et al.Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J].J Clin Invest,2001,108:1875-1881.

共引文献13

同被引文献96

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部